The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant potential in clinical trials for managing obesity. Unlike some current weight loss approaches, retatrutide appears to provide a greater substantial reduction in body mass and benefit metabolic function,